Spotlight Clinical, Medical & Diagnostic Products Co-Development of Revolutionary New MR-Guided Radiation Therapy System
Varian Medical Systems, Inc and IMRIS, Inc have concluded an agreement to co-develop an innovative new MR-guided radiation therapy system for use in treating a variety of cancers. Under the terms of the agreement, the two companies will develop a solution that combines IMRIS's proprietary MR imaging technology with Varian's recently introduced TrueBeam™ system, to enable the use of magnetic resonance imaging (MRI) during radiotherapy treatments for cancer. Launched in April 2010, Varian's TrueBeam system for radiotherapy and radiosurgery offers unprecedented speed and accuracy and has the ability to deliver treatments up to 50% faster, with a dose delivery rate of up to double the maximum of earlier, industry-leading Varian systems.
MR is the gold standard for soft tissue imaging. By leveraging IMRIS's proprietary technology and integrating the exquisite detail of MR imaging with the extensive treatment delivery capabilities of the TrueBeam system, the two companies expect to enhance the effectiveness of radiation therapy.
The solution will be designed to permit a high-field MRI scanner to move in and out of the radiation therapy room on demand, providing MR imaging to very precisely confirm a tumour's location prior to treatment, and again during the session as needed, all without having to move the patient from the treatment couch or transport the patient to and from another room, as would be required today. Consistent with IMRIS's systems for neurosurgery, neurovascular and cardiac applications, the radiation therapy systems are expected to be offered as multi-room configurations and include independent MR-simulation capabilities for the MR system to further enhance financial utility for hospitals.
Following successful completion of the development stage of this project, and subject to necessary regulatory approvals, the companies anticipate co-branding the new MR-guided radiation therapy suite and leveraging Varian's global presence and leadership position in the fields of radiotherapy and radiosurgery to market the new product.
Circle no. 89
Diagnostic Intelligence Business Analytics Solution Sunquest Information Systems®
has released its Diagnostic Intelligence™ solution, enabling laboratories to more effectively manage key clinical and operational performance indicators. This innovative solution delivers actionable, real-time information, displayed in easy-to-interpret dashboards.
Diagnostic Intelligence provides a suite of information analysis capabilities that enable immediate and data-driven decisions to improve safety and workflow, including measuring lab result turnaround times, critical test volumes and lab productivity on a minute-by-minute basis, as well as proactively monitoring key performance indicators, such as hospital acquired infection rates and overall profitability of the service.
“This innovative solution delivers information in an easily accessible manner, enabling real time performance management and providing enhanced value to laboratory leadership,” according to Richard Atkin, President and CEO of Sunquest. “Our customer research and feedback has clearly shown the need for this innovative technology.”
“The Sunquest Diagnostic Intelligence solution provides the capability to measure and report against key business metrics, enabling our customers to deliver mission critical laboratory services to their enterprise.”
Scaling New Heights in Research Circle no. 90
Suicidality Monitoring in Clinical Trials
High Speed Personal Micro-Centrifuge
Powerful centrifuge force 15100g, broad application range
Large LCD display provides all visual information
One-knob input, fast and easy operation
High speed, low noise
ERT announces that a recent survey of over 250 respondents reported that all clinicians polled found the Columbia Suicide Severity Rating Scale (C-SSRS) to be an effective method for prospectively monitoring suicidality. Furthermore, 99% of respondents thought the self-rated eC-SSRS would be an effective approach to meeting this new regulatory requirement. The eC-SSRS is a pioneering self-rated version of the C-SSRS that coordinates the patient reported input with the investigators’ review. These findings are supported by users of the eC-SSRS.
High Speed Refrigerated Micro-Centrifuge
Brushless motor drive, maintenance free
Powerful compressor and cooling system, fast cooling Maintains 4
at maximum
speed to protect precious samples
your budget
The poll was conducted during a recent webinar entitled, ‘Suicidality Monitoring in Clinical Trials’, with presentations provided by collaborators in the development of the eC- SSRS. The need for improved and more standardised suicidality monitoring was highlighted and the advantages of the C-SSRS verses only documenting spontaneous adverse events. The C-SSRS has been identified by the FDA as an acceptable assessment instrument for prospectively monitoring suicidal behaviors in clinical trials. The webinar also highlighted that a more consistent and systematic assessment, such as eC-SSRS combined with clinician review, would more clearly delineate the relationship between suicidal adverse events and medication treatment with more meaningful data within a study, as well as across studies, improving pooled analyses.
Dragon Laboratory Instruments Limited
Tel86-10-85653451/52/53 Fax86-10-85653383 E-mail
info@dragon-lab.com Http//
www.dragon-lab.com
ERT’s eC-SSRS solution provides customers with a scientifically sound, cost-effective and convenient method of prospectively monitoring for suicidality and has been designed in line with FDA requirements. Data was presented from the successful eC-SSRS validation study sponsored by a major pharmaceutical company with results demonstrating high levels of feasibility, reliability and validity for assessing suicidality and protecting patient safety. Many large and mid-size pharmaceutical companies are choosing to implement the eC-SSRS solution.
Using this approach can also lessen site burden and reduce sponsor costs by as much as 45%. The results of the webinar poll indicated that 97% of study managers thought that using the coordinated self-rated eC-SSRS verses a clinician-only administered approach could reduce their cost.
Circle no. 91 Circle no. 92 Circle no. 93
NEW!
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
